{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T12:41:39Z","timestamp":1786711299445,"version":"build-2736575974"},"reference-count":52,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The objective of this study is to review the efficacy and safety of doravirine\/islatravir for the treatment of HIV-1 infection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>\n                      A literature search was conducted in PubMed and Google Scholar (January 2016\u2013June 2026) using the search terms\n                      <jats:italic toggle=\"yes\">doravirine<\/jats:italic>\n                      or\n                      <jats:italic toggle=\"yes\">MK-1439<\/jats:italic>\n                      and\n                      <jats:italic toggle=\"yes\">islatravir<\/jats:italic>\n                      or\n                      <jats:italic toggle=\"yes\">MK-8591<\/jats:italic>\n                      . Other resources included abstracts presented at recent conferences and the prescribing information.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction:<\/jats:title>\n                    <jats:p>All English-language studies assessing the efficacy and safety of doravirine\/islatravir for the treatment of HIV-1 infection were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>Doravirine is an established second-generation nonnucleoside reverse transcriptase inhibitor. Islatravir is a new nucleoside reverse transcriptase inhibitor that uniquely interferes with translocation and is highly active against HIV-1. Doravirine\/islatravir once daily was shown to be safe and effective in three phase 3 clinical trials, using a lower dose of islatravir (0.25 mg), after a higher dose (0.75 mg) was shown in earlier trials to reduce total lymphocyte and CD4+ T-cell counts. The FDA approved this combination for the treatment of HIV-1 infection in adults who are virologically suppressed on stable antiretroviral therapy with no history of virologic treatment failure and no known resistance to doravirine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to Patient Care and Clinical Practice in Comparison to Existing Drugs:<\/jats:title>\n                    <jats:p>Doravirine\/islatravir is the first integrase strand transfer inhibitor-free 2-drug regimen indicated for the treatment of HIV-1 infection. The combination could be useful for patients who want to simplify their regimen and those who cannot receive an integrase inhibitor.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Doravirine\/islatravir is safe and effective as a 2-drug regimen for the treatment of HIV-1 infection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280261472079","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T09:24:51Z","timestamp":1786440291000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Doravirine\/Islatravir: A 2-Drug Regimen for the Treatment of HIV-1 Infection"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1775-9497","authenticated-orcid":false,"given":"Elias B.","family":"Chahine","sequence":"first","affiliation":[{"name":"Lloyd L. Gregory School of Pharmacy, Palm Beach Atlantic University, West Palm Beach, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6601-9893","authenticated-orcid":false,"given":"David E.","family":"Koren","sequence":"additional","affiliation":[{"name":"Temple University Hospital, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafik","family":"Samuel","sequence":"additional","affiliation":[{"name":"Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harrison","family":"Van der Kloot","sequence":"additional","affiliation":[{"name":"Temple University Hospital, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6559-0684","authenticated-orcid":false,"given":"Elizabeth M.","family":"Sherman","sequence":"additional","affiliation":[{"name":"Nova Southeastern University College of Pharmacy, Davie, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61809-7"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.278.5341.1295"},{"key":"e_1_3_2_4_2","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Published 2026. Accessed June 16 2026. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-arv\/"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-022-01003-3"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(22)00249-1"},{"key":"e_1_3_2_7_2","unstructured":"Merck News Release. FDA approved Merck\u2019s once-daily IDVYNSOTM (doravirine\/islatravir). Published April 21 2026. Accessed June 16 2026. https:\/\/www.merck.com\/news\/fda-approves-mercks-once-daily-idvynso-doravirine-islatravir\/"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms10020433"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01379-9"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01945-2"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01948-8"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(26)00033-0"},{"key":"e_1_3_2_13_2","unstructured":"Idvynso (doravirine and islatravir). Package insert. Merck Sharp & Dohme; 2026."},{"key":"e_1_3_2_14_2","unstructured":"Delstrigo (doravirine lamivudine and tenofovir disoproxil fumarate). Package insert. Merck Sharp & Dohme; 2025."},{"key":"e_1_3_2_15_2","unstructured":"Pifeltro (doravirine). Package insert. Merck Sharp & Dohme; 2025."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(19)30372-8"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M114.562694"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2013.12.070"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000471"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13048"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00931-22"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01030-24"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1177\/1060028019869641"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-021-01046-1"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-020-00934-2"},{"issue":"1","key":"e_1_3_2_26_2","first-page":"166","article-title":"Efficacy and safety of doravirine\/islatravir (100\/0.25 mg) in adults with HIV and renal impairment (Abstract 519)","volume":"34","author":"Post FA","year":"2026","unstructured":"Post FA, Kumar P, Orkin CM, et al. Efficacy and safety of doravirine\/islatravir (100\/0.25 mg) in adults with HIV and renal impairment (Abstract 519). Top Antivir Med. 2026;34(1):166.","journal-title":"Top Antivir Med"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01553-24"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.857"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002879"},{"key":"e_1_3_2_30_2","unstructured":"Correll T Molina J Klopfer S et al. Total lymphocyte and CD4+ T-cell count changes in participants receiving islatravir (0.25 0.75 and 2.25 mg QD) and doravirine +\/- lamivudine: post-hoc analysis from a phase 2b dose-ranging study (P011). International Congress on Drug Therapy in HIV Infection (HIV Glasgow) abstract O46; 2022."},{"key":"e_1_3_2_31_2","unstructured":"Merck News Release. Merck announces clinical holds on studies evaluating islatravir for the treatment and prevention of HIV-1 infection. Published December 13 2021. Accessed June 16 2026. https:\/\/www.merck.com\/news\/merck-announces-clinical-holds-on-studies-evaluating-islatravir-for-the-treatment-and-prevention-of-hiv-1-infection\/"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(24)00031-6"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(24)00030-4"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaf077"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000004367"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf695.562"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.13212"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00458-24"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)02167-1"},{"key":"e_1_3_2_40_2","unstructured":"Orkin C Mngqibisa R Velez JD et al. Switch to DOR\/ISL (100\/0.25 mg) QD from oral ART: week 96 update from an open-label phase 3 study. Published February 2026. Accessed June 16 2026. https:\/\/www.natap.org\/2026\/CROI\/croi_05.htm"},{"key":"e_1_3_2_41_2","unstructured":"Colson AE Mills AM Ramgopal M et al. Switch to DOR\/ISL (100\/0.25 mg) QD from BIC\/FTC\/TAF: 96-week update from a blinded phase 3 study. Published February 2026. Accessed June 16 2026. https:\/\/www.natap.org\/2026\/CROI\/croi_04.htm"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-026-04117-4"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1080\/25787489.2026.2698230"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00133-22"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiag257"},{"key":"e_1_3_2_46_2","unstructured":"Wensing AM Calvez V Ceccherini-Silbertstein F et al. Current evidence on islatravir drug resistance and implications for future HIV treatment. Accessed June 16 2026. https:\/\/www.iasusa.org\/tam-34-1-wensing\/"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(18)30021-3"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy540"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02223-21"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01216-21"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(21)00021-7"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.3390\/v13081566"},{"key":"e_1_3_2_53_2","volume-title":"Poster PI-018 Presented at ASCPT 2026 Annual Meeting","author":"Gillespie G","unstructured":"Gillespie G, Weissler V, Longo D, et al. A randomized, open-label, phase 1 drug-drug interaction study to evaluate the impact of lamivudine on the pharmacokinetics of islatravir in healthy adults. Poster PI-018 Presented at ASCPT 2026 Annual Meeting; March 4-6, 2026; Aurora, CO."}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280261472079","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280261472079","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280261472079","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T12:18:39Z","timestamp":1786709919000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280261472079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":52,"alternative-id":["10.1177\/10600280261472079"],"URL":"https:\/\/doi.org\/10.1177\/10600280261472079","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]},"article-number":"10600280261472079"}}